Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone.

Ann Oncol · 2012 · PMC3403730 · PMID 22734013

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

Its superiority over paracentesis was demonstrated in terms of puncture-free survival in a randomised clinical trial: puncture-free survival was significantly longer in the catumaxomab group (median 46 days) than in the control group (median 11 days), and overall survival showed a positive trend for the catumaxomab group [ 5 ].

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.